ARCH Venture Fund XIII, L.P.

ARCH Venture Fund XIII, L.P. is listed in filings as 10% Owner at Lyell Immunopharma, Inc.. This profile follows SEC Form 4 activity through Mar 9, 2026, including purchase activity. Recent filings connect the profile to Lyell Immunopharma, Inc. (LYEL). The current snapshot covers public activity from Mar 9, 2026. Reported amounts are shown as $12.5M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.